LUOXIN PHARMACEUTICALS GROUP STOCK CO., LTD. Financials Luoxin Pharmaceuticals Group Stock Co., Ltd.
Equities
002793
CNE1000026S7
Pharmaceuticals
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.06 CNY | +3.69% |
|
+5.42% | -5.60% |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| Capitalization 1 | 15,215 | 15,181 | 8,342 | 5,829 |
| Enterprise Value (EV) 1 | 15,380 | 16,004 | 10,513 | 6,655 |
| P/E ratio | 47.1 x | 37 x | -8.92 x | -8.79 x |
| Yield | 0.48% | 0.29% | - | - |
| Capitalization / Revenue | 2.5 x | 2.34 x | 2.33 x | 2.47 x |
| EV / Revenue | 2.52 x | 2.47 x | 2.93 x | 2.82 x |
| EV / EBITDA | 26.2 x | 22.7 x | -7.53 x | -23 x |
| EV / FCF | -2,66,72,978 x | -2,55,51,195 x | -1,68,86,588 x | 49,72,910 x |
| FCF Yield | -0% | -0% | -0% | 0% |
| Price to Book | 3.77 x | 3.46 x | 2.63 x | 2.36 x |
| Nbr of stocks (in thousands) | 14,67,223 | 14,63,956 | 10,87,588 | 10,87,588 |
| Reference price 2 | 10.37 | 10.37 | 7.670 | 5.360 |
| Announcement Date | 28/04/21 | 04/03/22 | 27/04/23 | 26/04/24 |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 6,211 | 7,589 | 6,096 | 6,478 | 3,588 | 2,364 |
| EBITDA 1 | 583.7 | 835.1 | 587.4 | 704.1 | -1,395 | -289.8 |
| EBIT 1 | 460.1 | 682.1 | 418.1 | 519.6 | -1,600 | -479.6 |
| Operating Margin | 7.41% | 8.99% | 6.86% | 8.02% | -44.6% | -20.29% |
| Earnings before Tax (EBT) 1 | 570.6 | 724.2 | 408.9 | 485.2 | -1,463 | -604.1 |
| Net income 1 | 512.3 | 634 | 322.3 | 406.1 | -1,226 | -661.1 |
| Net margin | 8.25% | 8.35% | 5.29% | 6.27% | -34.16% | -27.97% |
| EPS 2 | 0.4800 | 0.5700 | 0.2200 | 0.2800 | -0.8600 | -0.6100 |
| Free Cash Flow | - | -238.8 | -576.6 | -626.4 | -622.6 | 1,338 |
| FCF margin | - | -3.15% | -9.46% | -9.67% | -17.35% | 56.61% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share 2 | 0.3000 | 0.0500 | 0.0500 | 0.0300 | - | - |
| Announcement Date | 27/04/20 | 27/04/20 | 28/04/21 | 04/03/22 | 27/04/23 | 26/04/24 |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | 165 | 823 | 2,171 | 825 |
| Net Cash position 1 | 310 | 319 | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | 0.2801 x | 1.169 x | -1.556 x | -2.847 x |
| Free Cash Flow | - | -239 | -577 | -626 | -623 | 1,338 |
| ROE (net income / shareholders' equity) | - | 18.3% | 8.24% | 9.28% | -31.3% | -26.2% |
| ROA (Net income/ Total Assets) | - | 6.35% | 3.44% | 3.77% | -11.4% | -4.53% |
| Assets 1 | - | 9,981 | 9,365 | 10,768 | 10,786 | 14,596 |
| Book Value Per Share 2 | 1.540 | 2.560 | 2.750 | 3.000 | 2.920 | 2.270 |
| Cash Flow per Share 2 | 0.4300 | 0.7700 | 0.8800 | 1.370 | 1.320 | 0.6400 |
| Capex 1 | 364 | 581 | 361 | 309 | 195 | 242 |
| Capex / Sales | 5.85% | 7.65% | 5.92% | 4.77% | 5.43% | 10.25% |
| Announcement Date | 27/04/20 | 27/04/20 | 28/04/21 | 04/03/22 | 27/04/23 | 26/04/24 |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -5.60% | 734M | |
| +31.37% | 588B | |
| -2.60% | 364B | |
| +20.83% | 326B | |
| +5.69% | 285B | |
| +14.83% | 239B | |
| +9.93% | 210B | |
| -6.95% | 200B | |
| +10.77% | 167B | |
| +0.10% | 161B |
- Stock Market
- Equities
- 002793 Stock
- Financials Luoxin Pharmaceuticals Group Stock Co., Ltd.